T. Rowe Price Investment Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

T. Rowe Price Investment Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,325,491	Closed	-$5.42M	–	660
2024 Q2	$5.42M	Sell	1,325,491 -1,993,595	-60%	-$22.3M	﹤0.01%	571
2024 Q1	$52.3M	Buy	3,319,086 +977,303	+42%	+$13.4M	0.03%	389
2023 Q4	$35.5M	Buy	2,341,783 +369,299	+19%	+$5.39M	0.02%	434
2023 Q3	$39.6M	Sell	1,972,484 -26,870	-1%	-$682K	0.03%	396
2023 Q2	$56.4M	Sell	1,999,354 -11,055	-0.5%	-$265K	0.04%	362
2023 Q1	$34.6M	Sell	2,010,409 -200,033	-9%	-$4.05M	0.02%	411
2022 Q4	$44.5M	Buy	2,210,442 +1,773	+0.1%	+$38.1K	0.03%	369
2022 Q3	$47.8M	Buy	+2,208,669	New	+$60.4M	0.04%	352

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

T. Rowe Price Investment Management's ZNTL Position: Q3 2024 in Review

T. Rowe Price Investment Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 1,325,491 shares — an estimated $5.42M sold.

T. Rowe Price Investment Management first reported a position in ZNTL in Q3 2022 and held it in 8 quarters. The position peaked at $56.4M in Q2 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

T. Rowe Price Investment Management reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
T. Rowe Price Investment Management sold 1,325,491 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $5.42M.
T. Rowe Price Investment Management first reported a position in Zentalis Pharmaceuticals in Q3 2022 and held it in 8 quarters.
T. Rowe Price Investment Management's Zentalis Pharmaceuticals position peaked at $56.4M in Q2 2023.
136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on T. Rowe Price Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.